(19)
(11) EP 3 242 936 A1

(12)

(43) Date of publication:
15.11.2017 Bulletin 2017/46

(21) Application number: 16700156.9

(22) Date of filing: 06.01.2016
(51) International Patent Classification (IPC): 
C12N 9/64(2006.01)
A61K 38/48(2006.01)
 A61K 38/36(2006.01)
C07K 14/745(2006.01)
(86) International application number:
PCT/EP2016/050134
(87) International publication number:
WO 2016/110510 (14.07.2016 Gazette 2016/28)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 07.01.2015 EP 15305010

(71) Applicants:
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
    75013 Paris (FR)
  • Universite Paris-Sud
    91400 Orsay (FR)

(72) Inventors:
  • CHRISTOPHE, Olivier
    94276 Le Kremlin-Bicêtre Cedex (FR)
  • LENTING, Petrus
    94276 Le Kremlin-Bicêtre Cedex (FR)
  • DENIS, Cécile
    94276 Le Kremlin-Bicêtre Cedex (FR)

(74) Representative: Collin, Matthieu 
Inserm-Transfert Paris Biopark 7, rue Watt
75013 Paris
75013 Paris (FR)

   


(54) MUTATED FACTOR X POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF HAEMOPHILIA